Latest News

Real-world data linked semaglutide use to reduced liver stiffness and improved liver outcomes, with some benefits occurring independently of weight loss.

Jessica Lewis-Gonzalez, PharmD, BCOP, discusses how pharmacists can layer mediator-symptom management with cytoreductive or targeted therapy in systemic mastocytosis (SM) and interdisciplinary communication.

Residency ranking often shifts from structured metrics to “fit” and vibes, risking bias toward familiarity; refocus decisions on evidence, values, and potential.

The approval clears the way for a new vaccine option for older adults ahead of the 2026 to 2027 flu season.

Reflections on the 2025-2026 AACP Argus Commission Forecast

In adults with alcohol use disorder and diabetes or obesity, semaglutide or tirzepatide lowered hospitalization risk across 4 target trial emulations.

Hannaford's Sara Lane, PharmD, shares how standardized workflows and a growing technician immunizer program have driven measurable gains in vaccination rates.

A review offering guidance to pharmacists on the importance of peer review as well as a tutorial on how to perform and respond to peer review.

An investigational KRAS-targeted peptide vaccine generated durable immune responses and demonstrated early potential to intercept pancreatic cancer development in high-risk patients.

Schwartz must immediately address a measles crisis that has reached a 35-year high in the US, as well as a growing Cyclospora outbreak

This article highlights the efficacy and safety data of denileukin diftitox-cxdl for the treatment of relapsed or refractory cutaneous T-cell lymphoma.

The findings point to persistent vaccine hesitancy and access gaps in the years since the COVID-19 pandemic, with authors calling for stronger clinician recommendations and school-based vaccination sites.

In a phase 4 study, 90.9% of patients receiving preoperative suzetrigine-based multimodal therapy avoided opioid rescue after aesthetic or reconstructive surgery.

The future of 340B depends on integrating quality, compliance, technology, and pharmacist-led care to improve patient outcomes and strengthen audit readiness.

FDA-approved colorectal cancer blood tests—Shield, Epi proColon, SimpleScreen—expand blood-based screening, but positives still need colonoscopy.

Revumenib and ziftomenib in NPM1-mutated AML: practical guidance on differentiation syndrome, QTc monitoring, and drug interactions.

Zongertinib offers durable activity in HER2-mutant NSCLC while highlighting pharmacists’ essential role in biomarker verification, dosing, medication review, adherence, and toxicity management.

ASCO 2026 spotlights PROTEUS shifts, new breast cancer data, lung cancer treatment advances, and daxonrasib gains hope in pancreatic cancer.

A randomized trial found that medically tailored groceries cut hemoglobin A1C by 0.40 points and sharply improved food security in adults with type 2 diabetes.

Pafolacianine enables fluorescence-guided lung cancer surgery, with inpatient pharmacy integral to safe procurement, preparation, and interdisciplinary coordination.

From isotope decay to patient access, radiopharmaceuticals present unique challenges for oncology pharmacists.